[New views on therapy of Raynaud's syndrome. Preliminary note].
The action of Prazosin, a hypotensive drug which has been found to possess excellent therapeutic qualities for the syndrome's asphyxial attacks through its sympathicolytic and arteriolar vasodilatation action, was studied in Raynaud's syndrome. The early clinical results were highly encouraging.
D000293:Adolescent; D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000188:drug therapy*
D011799:Quinazolines; D011224:Prazosin
Nuove vedute di terapia della sindrome di Raynaud. Nota preliminare.